We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Image Scan Holdings Plc | LSE:IGE | London | Ordinary Share | GB0031410581 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 1.20 | 1.10 | 1.30 | 1.20 | 1.20 | 1.20 | 28,000 | 07:30:07 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Photographic Equip & Supply | 2.96M | 124k | 0.0009 | 13.33 | 1.64M |
From Apr 2019 to Apr 2024
TIDMIGE
RNS Number : 2166L
Image Scan Holdings PLC
29 April 2020
Image Scan Holdings plc
Interim Report 2020
29/04/2020
IMAGE SCAN HOLDINGS PLC
("Image Scan" or the "Company")
(AIM: IGE)
INTERIM RESULTS
Image Scan, (AIM: IGE) specialists in the field of X-ray imaging for the security and industrial inspection markets, today announces its interim results for the six months ended 31 March 2020. While the performance during the first six months was ahead of our expectations, the Board expects second half trading to be significantly impacted by the COVID-19 pandemic.
Financial summary:
-- Revenue increased over 60% to GBP2.3m (2019: GBP1.4m) -- Gross profit margin steady at 45% (2019: 47%) -- Profit before taxation of GBP180k (2019: loss of GBP178k) -- Period end bank balance of GBP1.1m (2019: GBP750k) -- Order intake GBP1.5m (2019: GBP2.1m) -- Period end order book of GBP0.9m (2019: GBP1.0m)
-- Earnings guidance raised for FY 2020 but suspended for FY 2021 and beyond due to expected impact of COVID-19 on individual Governments' purchasing
Operational highlights:
-- Large portable X-ray contract delivered to customer -- Number of portable X-ray systems sold doubled compared to prior year -- First X-ray images taken with prototype of new Axis X-ray system -- UK distribution agreement signed with Italian X-ray company, Gilardoni -- New initiative to develop sales in North America -- Company continues development and manufacturing through COVID-19 crisis
The Board considers that the Company has a sufficient orderbook and short-term prospects of new orders to raise its earnings guidance for the year ending 30 September 2020 to sales of GBP3.3m and a loss before tax of approximately GBP90k (compared to current market expectations of sales of GBP2.99m with a loss before tax of GBP197k). However, with uncertainty over international Government spending on security systems during the COVID-19 pandemic, the Board is suspending guidance for FY2021 and beyond.
Bill Mawer, Chairman and Chief Executive Officer of Image Scan commented: "This strong first half performance, and the healthy period-end cash balance, puts the Company in a relatively strong position to weather the COVID-19 crisis. With outstanding support from our staff, we have, so far, been able to maintain both manufacturing and product development activity and have continued to make customer sales. Order intake has been impacted, with our Government customers focussing on healthcare rather than security, and we expect this to continue for some months."
For further information on the Company, please visit: www.ish.co.uk and for further information on its
Hot Features
Premium
products, please visit: www.3dx-ray.com
Enquiries:
Image Scan Holdings plc Tel: +44 (0) 1509 817
William Mawer, Chairman and Chief Executive Officer 400
Sarah Atwell King, Finance Director and Company ir@ish.co.uk
Secretary
----------------------
Cantor Fitzgerald Europe Tel: +44 (0) 207 894
Rick Thompson / Will Goode (Corporate Finance) 7000
----------------------
Chairman's statement
Introduction
Image Scan Holdings plc is a specialist in innovative X-ray technology, operating globally in the security and industrial inspection sectors. The Company's principal activity is the design, manufacture, and supply of both portable and fixed X-ray security screening systems to governments, security organisations and law enforcement agencies. The Company also supplies high-quality image acquisition systems for non-destructive testing to commercial organisations worldwide.
Financial results
Revenues for the six months ended 31 March 2020 were up over 60% at GBP2.3m (2019: GBP1.4m) which included a doubling of portable X-ray unit sales numbers compared to the same period in 2019, while the gross margin on sales held steady at 45% (2019: 47%).
Overhead costs declined slightly to GBP840k (2019: GBP854k) although investment in marketing was increased as the company looked to expand its global footprint. The business made a profit of GBP180k, turning around the loss in the same period last year (2019: loss of GBP178k).
Order intake, though smaller than the prior year was in line with the Board's expectations at GBP1.5m (2019: GBP2.1m), leaving the Company with a period end order book of GBP900k, most of which is scheduled for delivery in this financial year. Having reduced previously high levels of stock, period end cash increased to GBP1.1m (2019: GBP750k).
Overview
The strong portable X-ray order intake seen in the final quarter of FY19 continued into the first quarter of FY 20 with orders from all our main target regions. The large portable X-ray order announced in September 2019 has now been delivered and overall portable sales were more than twice those seen in the same period last year. Three valuable orders for industrial screening systems were also received, of which one has been completed. Aftermarket revenues have increased and included valuable spares orders for a large nuclear screening system originally delivered in 2015.
The product development strategy includes a renewed and extended "Axis" range of X-ray screening systems, combining in-house developments with external technology partnerships. The prototype of a new security X-ray system developed under this plan has produced its first images and will be launched in the second half of FY 2020. Additionally, a UK distribution agreement has been signed with Italian X-ray company, Gilardoni. Work has also started on a broader range of partnerships.
The Company plans to increase its sales efforts in North America and has contracted a former US Marine, who is an experienced programme manager and senior Explosive Ordnance Disposal (EOD) technician. He is providing valuable support to our product development programmes, sharing his extensive user and technical knowledge. He has also started to conduct customer training programmes on the Company's behalf and is building our social media profile among the bomb technician community.
Outlook - COVID-19 and beyond
Having taken steps to ensure a COVID-19 safe working environment, our production facility remains open, and we are building both industrial and security X-ray machines for customers. Provided Government movement guidance remains as now, and our staff remain healthy, we expect to be able to deliver most of the GBP900k orderbook in this financial year.
Development staff are mostly working from home but use the engineering and test facilities at the site as required, and the product development programme continues to make good progress. In response to a decrease in activity we have selectively taken advantage of the UK Government's Coronavirus Job Retention Scheme and currently have some staff on furlough.
With our Government customers focussed on their COVID-19 response, security orders have declined, and we expect this to continue until normality is restored. However, some portable X-ray orders are still being received and we should be able to deliver those systems as normal. At the start of the pandemic we experienced some supply chain issues in China, but we believe these to have largely been resolved. Our major industrial customers, for whom we are a critical supplier, are being very supportive in ensuring prompt payments against equipment and support contracts.
We can't predict when the effects of the pandemic on the business will diminish, but we are managing cash carefully while continuing to invest in expanding our product range, aiming to position the business for a strong return as the crisis wanes.
Our staff at Image Scan continue to be enthusiastic, dedicated and creative and on behalf of my fellow Board members, I would like to formally thank all our personnel for their outstanding response to the current challenging circumstances.
Bill Mawer
Chairman and Chief Executive Officer
29/04/2020
Consolidated income statement
For the six months ended 31 March 2020
Six months Six months Year ended
ended ended 30 September
31 March 31 March
2020 2019 2019
(Unaudited) (Unaudited) (Audited)
Note GBP'000 GBP'000 GBP'000
Revenue 2,287 1,423 2,365
------------ ------------ -------------
Cost of sales (1,268) (747) (1,087)
------------ ------------ -------------
Gross profit 1,019 676 1,278
------------ ------------ -------------
Operating expenses (840) (854) (1,681)
------------ ------------ -------------
Operating profit/(loss) 179 (178) (403)
------------ ------------ -------------
Finance income 1 - 1
------------ ------------ -------------
Profit/(loss) before taxation 180 (178) (402)
------------ ------------ -------------
Taxation - - 34
------------ ------------ -------------
Profit/(loss) for the period 180 (178) (368)
------------ ------------ -------------
Pence Pence Pence
Earnings per share
---- ----- ------ ------
Basic profit per share [3] 0.13 (0.13) (0.27)
---- ----- ------ ------
Diluted profit per share 0.13 (0.13) (0.27)
----- ------ ------
Consolidated statement of changes in equity
For the six months ended 31 March 2020
Six months Six months Year ended
ended ended 30 September
31 March 31 March
2020 2019 2019
(Unaudited) (Unaudited) (Audited)
Note GBP'000 GBP'000 GBP'000
Opening equity shareholders' funds 1,268 1,630 1.630
------------ ------------ -------------
Share-based payments [4] 4 3 6
----- ------------ ------------ -------------
Profit/loss) attributable to equity
shareholders 180 (178) (368)
------------ ------------ -------------
Closing equity shareholders' funds 1,452 1,455 1,268
------------ ------------ -------------
Consolidated statement of financial position
As at 31 March 2020
As at As at
31 March
2020 As at 30 September
(Unaudited) 31 March
2019 2019
GBP'000 (Unaudited) (Audited)
GBP'000 GBP'000
Non-current assets
------------ ------------ -------------
Intangible and tangible assets 40 86 44
------------ ------------ -------------
40 86 44
------------ ------------ -------------
Current assets
------------ ------------ -------------
Inventories 439 804 783
------------ ------------ -------------
Trade and other receivables 697 499 664
------------ ------------ -------------
Cash and cash equivalents 1,140 750 641
------------ ------------ -------------
2,276 2,053 2,088
------------ ------------ -------------
Total assets 2,316 2,139 2,132
------------ ------------ -------------
Current liabilities
------------ ------------ -------------
Trade and other payables 832 646 848
------------ ------------ -------------
Non-current liabilities
------------ ------------ -------------
Provisions for liabilities and charges 32 38 16
------------ ------------ -------------
Total liabilities 864 684 864
------------ ------------ -------------
Net assets 1,452 1,455 1,268
------------ ------------ -------------
Equity
------------ ------------ -------------
Share capital 1,363 1,363 1,363
------------ ------------ -------------
Share premium account 8,328 8,328 8,328
------------ ------------ -------------
Retained earnings (8,239) (8,236) (8,423)
------------ ------------ -------------
Equity shareholders' funds 1,452 1,455 1,268
------------ ------------ -------------
Consolidated cash flow statement
For the six months ended 31 March 2020
Six months Six months Year ended
ended ended 30 September
31 March 31 March
2020 2019 2019
(Unaudited) (Unaudited) (Audited)
GBP'000 GBP'000 GBP'000
Cash flows from operating activities
------------ ------------ -------------
Operating profit/(loss) 179 (178) (403)
------------ ------------ -------------
Adjustments for:
------------ ------------ -------------
Depreciation 11 12 24
------------ ------------ -------------
Impairment of inventories 14 19 13
------------ ------------ -------------
Increase/(decrease) in provision for
warranty 16 3 (19)
------------ ------------ -------------
Decrease in inventories 330 115 142
------------ ------------ -------------
Increase/(decrease) in trade and other
receivables (143) 237 120
------------ ------------ -------------
Increase/(decrease) in trade and other
payables 29 (264) (62)
------------ ------------ -------------
Share-based payment charge 4 3 6
------------ ------------ -------------
Net cash used in operating activities 440 (53) (179)
------------ ------------ -------------
Corporation tax recovered 64 47 64
------------ ------------ -------------
Net cash outflow from operating activities 504 (6) (115)
------------ ------------ -------------
Cash flows from investing activities
------------ ------------ -------------
Interest received 1 - 1
------------ ------------ -------------
Purchase of intangible and tangible
assets (6) (26) (27)
------------ ------------ -------------
Net cash used in investing activities (5) (26) (26)
------------ ------------ -------------
Cash flows from financing activities
------------ ------------ -------------
Proceeds from issue of share capital - - -
------------ ------------ -------------
Net cash from financing activities - - -
------------ ------------ -------------
Net increase/(decrease) in cash and
cash equivalents 499 (32) (141)
------------ ------------ -------------
Cash and cash equivalents at beginning
of period 641 782 782
------------ ------------ -------------
Cash and cash equivalents at end of
period 1,140 750 641
------------ ------------ -------------
Notes to the unaudited interim financial statements
For the six months ended 31 March 2020
1 Basis of preparation
The interim financial statements, which are unaudited, have been prepared on the basis of the accounting policies expected to apply for the financial year to 30 September 2020 and in accordance with recognition and measurement principles of International Financial Reporting Standards ('IFRSs') as endorsed by the European Union. The accounting policies applied in the preparation of these interim financial statements are consistent with those used in the financial statements for the year ended 30 September 2019.
The interim financial statements do not include all of the information required for full annual financial statements and do not comply with all the disclosures in IAS 34 'Interim financial reporting'. Accordingly, whilst the interim statements have been prepared in accordance with IFRSs, they cannot be construed as being in full compliance with IFRSs.
The financial information for the year ended 30 September 2019 does not constitute the full statutory accounts for that period. The annual report and financial statements for the year ended 30 September 2019 have been filed with the Registrar of Companies. The Independent auditor's report on the report and financial statements for the year ended 30 September 2019 was unqualified, did not draw attention to any matters by way of emphasis, and did not contain a statement under Section 498(2) or 498(3) of the Companies Act 2006.
2 Going concern
The interim financial information has been prepared on a going concern basis, which assumes that the Company will have adequate resources to continue in operational existence for the foreseeable future.
3 Earnings per share ('EPS')
Basic earnings per ordinary share is based on the profit on ordinary activities before taxation of GBP180,400 and on 136,354,577 ordinary shares in issue throughout the period.
Diluted profit per share is calculated by adjusting the weighted average number of ordinary shares in issue on the assumption of conversion of dilutive potential ordinary shares, based on the share price at the end of the period. The Company's dilutive potential ordinary shares are shares issued under the Company's Enterprise Management Incentive ('EMI') scheme and options issued under the Company's Unapproved scheme.
4 IFRS 2 'Share-based payments'
Operating expenses includes a charge of GBP3,877 (2019: GBP2,777) after valuation of the Company's employee share option schemes in accordance with IFRS 2. Under this standard, the fair value of the options at the grant date is spread over the vesting period. These charges have been credited to equity in accordance with IFRS2 as presented in the consolidated statement of changes in equity.
5 Additional copies
Further copies of the 2020 interim report are available on the Company's website, www.ish.co.uk, and from the Company's registered office, 16-18 Hayhill Industrial Estate, Sileby Road, Barrow-upon-Soar, Leicestershire LE12 8LD.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
IR FLFVESEITFII
(END) Dow Jones Newswires
April 29, 2020 02:00 ET (06:00 GMT)
1 Year Image Scan Chart |
1 Month Image Scan Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
